Enhanced antitumor activity of low-dose continuous administration schedules of topotecan in prostate cancer

References

• Gulley J, Dahut W. Novel clinical trials in androgen-independent prostate cancer. Clin Prostate Cancer 2002; 1:51 - 57; PMID: 15046713
   PubMedGoogle Scholar
• Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177:2106 - 2131; PMID: 17509297; http://dx.doi.org/10.1016/j.juro.2007.03.003
   PubMed Web of Science ®Google Scholar
• Jani AB. Management strategies for locally advanced prostate cancer. Drugs Aging 2006; 23:119 - 129; PMID: 16536635; http://dx.doi.org/10.2165/00002512-200623020-00003
   PubMed Web of Science ®Google Scholar
• Rumohr JA, Chang SS. Current chemotherapeutic approaches for androgen-independent prostate cancer. Curr Opin Investig Drugs 2006; 7:529 - 533; PMID: 16784023
   PubMed Web of Science ®Google Scholar
• Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1:34 - 45; PMID: 11900250; http://dx.doi.org/10.1038/35094009
   PubMed Web of Science ®Google Scholar
• Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 8:12 - 23; PMID: 20859283; http://dx.doi.org/10.1038/nrclinonc.2010.136
   PubMed Web of Science ®Google Scholar
• Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4:423 - 436; PMID: 15170445; http://dx.doi.org/10.1038/nrc1369
   PubMed Web of Science ®Google Scholar
• Kerbel RS, Klement G, Pritchard KI, Kamen B. Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 2002; 13:12 - 15; PMID: 11863092; http://dx.doi.org/10.1093/annonc/mdf093
   PubMed Web of Science ®Google Scholar
• Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994; 271:58 - 65; PMID: 8066425; http://dx.doi.org/10.1038/scientificamerican0794-58
   PubMed Web of Science ®Google Scholar
• Berry W, Eisenberger M. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. Oncologist 2005; 10:30 - 39; PMID: 16368869; http://dx.doi.org/10.1634/theoncologist.10-90003-30
   PubMed Web of Science ®Google Scholar
• Lennernäs B, Albertsson P, Damber JE, Norrby K. Albertsson P, Damber J, Norrby K. Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: a quantitative study. APMIS 2004; 112:201 - 219; PMID: 15153162; http://dx.doi.org/10.1111/j.1600-0463.2004.apm1120306.x
   PubMed Web of Science ®Google Scholar
• Vogt T, Hafner C, Bross K, Bataille F, Jauch K, Berand A, et al. Antiangiogenetic therapy with pioglitazone, rofecoxib and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer 2003; 98:2251 - 2256; PMID: 14601096; http://dx.doi.org/10.1002/cncr.11775
   PubMed Web of Science ®Google Scholar
• Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 2006; 17:232 - 238; PMID: 16322118; http://dx.doi.org/10.1093/annonc/mdj066
   PubMed Web of Science ®Google Scholar
• Kamat AA, Kim T, Landen C Jr, Lu C, Han L, Lin Y, et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 2007; 67:281 - 288; PMID: 17210709; http://dx.doi.org/10.1158/0008-5472.CAN-06-3282
   PubMed Web of Science ®Google Scholar
• Bocci G, Falcone A, Fioravanti A, Orlandi P, Di Paolo A, Fanelli G, et al. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer 2008; 98:1619 - 1629; PMID: 18443598; http://dx.doi.org/10.1038/sj.bjc.6604352
   PubMed Web of Science ®Google Scholar
• Wang J, Lou P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003; 14:13 - 19; PMID: 12544254; http://dx.doi.org/10.1097/00001813-200301000-00003
   PubMed Web of Science ®Google Scholar
• Fontana A, Galli L, Fioravanti A, Orlandi P, Galli C, Landi L, et al. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib and dexamethasone in advanced hormone-refractory prostate cancer. Clin Cancer Res 2009; 15:4954 - 4962; PMID: 19622584; http://dx.doi.org/10.1158/1078-0432.CCR-08-3317
   PubMed Web of Science ®Google Scholar
• Bocci G, Nicolaou K, Kerbel R. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002; 62:6938 - 6943; PMID: 12460910
   PubMed Web of Science ®Google Scholar
• Miller KD, Sweeney C, Sledge G Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001; 19:1195 - 1206; PMID: 11181686
   PubMed Web of Science ®Google Scholar
• Doloff JC, Khan N, Ma J, Demidenko E, Swartz H, Jounaidi Y. Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine (Sup. Material). Curr Cancer Drug Targets 2009; 9:777 - 788; PMID: 19754361; http://dx.doi.org/10.2174/156800909789271503
   PubMed Web of Science ®Google Scholar
• O'Leary JJ, Shapiro RL, Ren CJ, Chuang N, Cohen HW, Potmesil M. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan and CPT-11 studied in the mouse cornea model. Clin Cancer Res 1999; 5:181 - 187; PMID: 9918217
   PubMed Web of Science ®Google Scholar
• Clements MK, Jones CB, Cumming M, Daoud SS. Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother Pharmacol 1999; 44:411 - 416; PMID: 10501915; http://dx.doi.org/10.1007/s002800050997
   PubMed Web of Science ®Google Scholar
• Petrangolini G, Pratesi G, De Cesare M, Supino R, Pisano C, Marcellini M, et al. Antiangiogenic effects of the novel camptothecin ST1481 (gimatecan) in human tumor xenografts. Mol Cancer Res 2003; 1:863 - 870; PMID: 14573787
   PubMed Web of Science ®Google Scholar
• Hsiang YH, Liu L. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988; 48:1722 - 1726; PMID: 2832051
   PubMed Web of Science ®Google Scholar
• Hudes GR, Kosierowski R, Greenberg R, Ramsey H, Fox S, Ozols R, et al. Phase II study of topotecan in metastatic hormone-refractory prostate cancer. Invest New Drugs 1995; 13:235 - 240; PMID: 8729952; http://dx.doi.org/10.1007/BF00873806
   PubMed Web of Science ®Google Scholar
• Klein CE, Tangen CM, Braun TJ, Hussain MH, Peereboom DM, Nichols CR, et al. SWOG-9510: evaluation of topotecan in hormone refractory prostate cancer: a Southwest Oncology Group study. Prostate 2002; 52:264 - 268; PMID: 12210486; http://dx.doi.org/10.1002/pros.10118
   PubMed Web of Science ®Google Scholar
• Tolis C, Peters GJ, Ferreira CG, Pinedo HM, Giaccone G. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer 1999; 35:796 - 807; PMID: 10505042; http://dx.doi.org/10.1016/S0959-8049(98)00425-0
   PubMed Web of Science ®Google Scholar
• Sun B, Zhang X, Talathi S, Cummings BS. Inhibition of Ca2+-independent phospholipase A2 decreases prostate cancer cell growth by p53-dependent and independent mechanisms. J Pharmacol Exp Ther 2008; 326:59 - 68; PMID: 18441250; http://dx.doi.org/10.1124/jpet.108.138958
   PubMed Web of Science ®Google Scholar
• Sun B, Zhang X, Yonz C, Cummings BS. Inhibition of calcium-independent phospholipase A2 activates p38 MAPK signaling pathways during cytostasis in prostate cancer cells. Biochem Pharmacol 2010; 79:1727 - 1735; PMID: 20171194; http://dx.doi.org/10.1016/j.bcp.2010.02.005
   PubMed Web of Science ®Google Scholar
• Kaiser MG, Parsa A, Fine R, Hall J, Chakrabarti I, Bruce J. Tissue distribution and antitumor activity of topotecan delivered by intracerebral clysis in a rat glioma model. Neurosurgery 2000; 47:1391 - 1398; PMID: 11126910; http://dx.doi.org/10.1097/00006123-200012000-00026
   PubMed Web of Science ®Google Scholar
• Soffer SZ, Kim E, Moore J, Huang J, Yokoi A, Manley C, et al. Novel use of an established agent: Topotecan is anti-angiogenic in experimental Wilms tumor* 1. J Pediatr Surg 2001; 36:1781 - 1784; PMID: 11733906; http://dx.doi.org/10.1053/jpsu.2001.28823
   PubMed Web of Science ®Google Scholar
• Horoszewicz JS, Leong S, Kawinski E, Karr J, Rosenthal H, Chu T, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43:1809 - 1818; PMID: 6831420
   PubMed Web of Science ®Google Scholar
• Kaighn ME, Narayan K, Ohnuki Y, Lechner J, Jones L. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979; 17:16 - 23; PMID: 447482
   PubMedGoogle Scholar
• Price PM, Safirstein RL, Megyesi J. The cell cycle and acute kidney injury. Kidney Int 2009; 76:604 - 613; PMID: 19536080; http://dx.doi.org/10.1038/ki.2009.224
   PubMed Web of Science ®Google Scholar
• Jiang M, Dong Z. Regulation and pathological role of p53 in cisplatin nephrotoxicity. J Pharmacol Exp Ther 2008; 327:300 - 307; PMID: 18682572; http://dx.doi.org/10.1124/jpet.108.139162
   PubMed Web of Science ®Google Scholar
• Cummings BS, Schnellmann RG. Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther 2002; 302:8 - 17; PMID: 12065694; http://dx.doi.org/10.1124/jpet.302.1.8
   PubMed Web of Science ®Google Scholar
• Megyesi J, Udvarhelyi N, Safirstein RL, Price PM. The p53-independent activation of transcription of p21WAF1/CIP1/SDI1 after acute renal failure. Am J Physiol 1996; 271:1211 - 1216; PMID:8997395; DOI:
   PubMedGoogle Scholar
• Niculescu AB III, Chen X, Smeets M, Hengst L, Prives C, Reed S. Effects of p21Cip1/Waf1 at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 1998; 18:629 - 643; PMID: 9418909
   PubMed Web of Science ®Google Scholar
• Dergham S, Dugan M, Joshi U, Chen Y, Du W, Smith D, et al. The clinical significance of p21WAF1/CIP-1 and p53 expression in pancreatic adenocarcinoma. Cancer 1997; 80:372 - 381; http://dx.doi.org/10.1002/(SICI)1097-0142(19970801)80:3<372::AIDCNCR4>3.0.CO;2-U
   PubMed Web of Science ®Google Scholar
• Aaltomaa S, Lipponen P, Eskelinen M, Ala-Opas M, Kosma V. Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer. Prostate 1999; 39:8 - 15; PMID: 10221260; http://dx.doi.org/10.1002/(SICI)1097-0045(19990401)39:1<8::AID-PROS2>3.0.CO;2-N
   PubMed Web of Science ®Google Scholar
• Gomyo Y, Ikeda M, Osaki M, Tatebe S, Tsujitani S, Ikeguchi M, et al. Expression of p21(waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 1997; 79:2067 - 2072; PMID: 9179052; http://dx.doi.org/10.1002/(SICI)1097-0142(19970601)79:11<2067::AIDCNCR3>3.0.CO;2-M
   PubMed Web of Science ®Google Scholar
• Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004; 17:292 - 306; PMID: 14976540; http://dx.doi.org/10.1038/modpathol.3800054
   PubMed Web of Science ®Google Scholar
• Tillmanns T, Buller R, Stewart C, Mac Eachern J, Schaiquevich P, Walker M, et al. Daily oral topotecan: Utilization of a metronomic dosing schedule to treat recurrent or persistent solid tumors. Chemotherapy 2008; 3:19 [Presented at American Society of Clinical Oncology Annual Meeting]
   Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55 - 63; PMID: 6606682; http://dx.doi.org/10.1016/0022-1759(83)90303-4
   PubMed Web of Science ®Google Scholar
• Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82:1107 - 1112; PMID: 2359136; http://dx.doi.org/10.1093/jnci/82.13.1107
   PubMed Web of Science ®Google Scholar
• Davol PA, Frackelton AR Jr. Targeting human prostatic carcinoma through basic fibroblast growth factor receptors in an animal model: characterizing and circumventing mechanisms of tumor resistance. Prostate 1999; 40:178 - 191; PMID: 10398280; http://dx.doi.org/10.1002/(SICI)1097-0045(19990801)40:3<178::AIDPROS6>3.0.CO;2-I
   PubMed Web of Science ®Google Scholar
• Geran R, Greenberg N, MacDonald M, Schumacher A, Abbott B. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. Cancer Chemother Rep 1972; 3:1 - 103
   Google Scholar
• Tardi P, Choice E, Masin D, Redelmeier T, Bally M, Madden TD. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Cancer Res 2000; 60:3389 - 3393; PMID: 10910044
   PubMed Web of Science ®Google Scholar
• Venditto VJ, Simanek EE. Cancer therapies utilizing the camptothecins: a review of the in vivo literature. Mol Pharm 2010; 7:307 - 349; PMID: 20108971; http://dx.doi.org/10.1021/mp900243b
   PubMed Web of Science ®Google Scholar
• Shah DK, Shin BS, Veith J, Toth K, Bernacki RJ, Balthasar JP. Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy. J Pharmacol Exp Ther 2009; 329:580 - 591; PMID: 19233938; http://dx.doi.org/10.1124/jpet.108.149443
   PubMed Web of Science ®Google Scholar
• Zastre J, Anantha M, Ramsay E, Bally M. Irinotecancisplatin interactions assessed in cell-based screening assays: cytotoxicity, drug accumulation and DNA adduct formation in an NSCLC cell line. Cancer Chemother Pharmacol 2007; 60:91 - 102; PMID: 17009029; http://dx.doi.org/10.1007/s00280-006-0353-z
   PubMed Web of Science ®Google Scholar